uniQure (NASDAQ:QURE) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

QURE has been the topic of several other research reports. Zacks Investment Research raised uniQure from a “sell” rating to a “hold” rating and set a $9.25 price objective on the stock in a research report on Wednesday, August 9th. Leerink Swann upped their price objective on uniQure from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Evercore ISI began coverage on uniQure in a research note on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price objective for the company. Oppenheimer reiterated a “hold” rating on shares of uniQure in a research note on Friday, November 24th. Finally, HC Wainwright began coverage on uniQure in a research note on Friday. They issued a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $18.75.

uniQure (QURE) traded up $0.42 during midday trading on Friday, reaching $15.56. The company had a trading volume of 536,307 shares, compared to its average volume of 395,893. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. uniQure has a one year low of $4.72 and a one year high of $21.35.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mangrove Partners lifted its position in shares of uniQure by 167.4% in the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after acquiring an additional 66,763 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in shares of uniQure in the third quarter valued at approximately $399,000. FMR LLC lifted its position in shares of uniQure by 4.1% in the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after acquiring an additional 61,650 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of uniQure by 33.5% in the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 14,659 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of uniQure by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after acquiring an additional 122,700 shares in the last quarter. Institutional investors and hedge funds own 24.87% of the company’s stock.

WARNING: “uniQure (QURE) Stock Rating Lowered by ValuEngine” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/02/uniqure-qure-stock-rating-lowered-by-valuengine.html.

uniQure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.